Physician profile
Daniel Ferrante
NPI 1316998859
$4,633.50
in general payments reported to CMS, 2019-2025
33 companies · $526 in 2025
The $526 reported for 2025 was more than what 81% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,926 · 2020: $172 · 2021: $275 · 2022: $659 · 2023: $340 · 2024: $736 · 2025: $526.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,516 · Education: $85.05.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,515.87 |
| Education | $85.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celularity INC. | $1,200.00 | 2019-2022 | |
| Abbvie INC. | $558.80 | 2019-2023 | |
| Applied Medical Resources Corporation | $245.38 | 2021 | |
| Astellas Pharma US INC | $239.51 | 2024-2025 | Veozah |
| Mayne Pharma Commercial LLC | $222.80 | 2022-2025 | |
| Allergan, INC. | $218.28 | 2019 | |
| Exeltis, USA INC. | $213.99 | 2019-2024 | Slynd |
| Millicent US INC | $211.39 | 2019-2025 | Femring, Femlyv, Intrarosa |
| Organon LLC | $179.84 | 2023-2025 | Nexplanon, Jada System |
| Therapeuticsmd, INC. | $147.17 | 2019-2022 | |
| Pfizer INC. | $143.16 | 2019-2025 | |
| Galderma Laboratories, L.P. | $137.60 | 2019 | |
| Avion Pharmaceuticals | $116.28 | 2019-2023 | Balcoltra |
| Sumitomo Pharma America, INC. | $95.71 | 2023-2025 | Myfembree |
| Exact Sciences Corporation | $95.52 | 2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Coopersurgical, INC. | $77.91 | 2024 | Summit Doppler, Endosee, Paragard T 380a |
| Amag Pharmaceuticals, INC. | $75.30 | 2019-2020 | |
| Sage Therapeutics, LLC | $71.19 | 2024-2025 | Zurzuvae |
| Bayer Healthcare Pharmaceuticals INC. | $64.53 | 2020-2025 | |
| Revance Therapeutics, INC. | $45.16 | 2024-2025 | Daxxify |
| Amgen INC. | $42.11 | 2019-2024 | Evenity, Prolia |
| Hologic Sales and Service, LLC | $36.26 | 2022-2025 | Myosure Tissue Removal Device |
| Myovant Sciences INC. | $27.86 | 2022 | |
| Vertical Pharmaceuticals, LLC | $27.32 | 2019-2020 | |
| Duchesnay USA Incorporated | $26.71 | 2019-2020 | |
| Dysis Medical, INC. | $19.79 | 2022 | |
| Corcept Therapeutics | $17.87 | 2024 | Korlym |
| Davol INC. | $17.49 | 2021 | |
| Pacira Pharmaceuticals Incorporated | $15.16 | 2023 | Exparel |
| Smith+Nephew, INC. | $15.00 | 2019 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $14.91 | 2022 | |
| Channel Medsystems, INC. | $13.50 | 2023 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$5.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Ferrante listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.